Skip to main content
. 2022 Apr 29;14(9):2219. doi: 10.3390/cancers14092219

Figure 3.

Figure 3

Combining ctDNA fraction/AR status and PSA kinetics (A), radiographic progression-free survival (B) and overall survival (C). Radiographic and PSA response was assessed according to PCWG3 criteria.